CD19 ELISA Kit

Name: CD19 ELISA Kit
SKU: DEIA-XYA358
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

cultured cells

Species Reactivity

Human; Mouse

Detection Method

Indirect ELISA

Intended Use

The CD19 Cell-Based ELISA Kit is a convenient, lysate-free, high throughput and sensitive assay kit that can monitor CD19 protein expression profile in cells. The kit can be used for measuring the relative amounts of CD19 in cultured cells as well as screening for the effects that various treatments, inhibitors (ie. siRNA or chemicals), or activators have on CD19.

Contents of Kit

1. 96-Well Cell Culture Clear-Bottom Microplate: 1 plate
2. 10x TBS: 24 mL (10x), Clear
3. Quenching Buffer: 24 mL (1x), Clear
4. Blocking Buffer: 50 mL (1x), Clear
5. 10x Wash Buffer: 50 mL (10x), Clear
6. 100x Anti-CD19 Antibody (Rabbit Polyclonal): 60 μL (100x), Purple
7. 100x Anti-GAPDH Antibody (Mouse Monoclonal): 60 μL (100x), Green
8. HRP-Conjugated Anti-Rabbit IgG Antibody: 6 mL (1x), Glass
9. HRP-Conjugated Anti-Mouse IgG Antibody: 6 mL (1x), Glass
10. Primary Antibody Diluent: 12 mL (1x), Clear
11. Ready-to-Use Substrate: 12 mL (1x), Brown
12. Stop Solution: 12 mL (1x), Clear
13. Crystal Violet Solution: 6 mL (1x), Glass
14. SDS Solution: 24 mL (1x), Clear
15. Adhesive Plate Seals: 4 seals

Storage

4°C/6 Months

Citations

Have you cited DEIA-XYA358 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Memory CD73(+)IgM(+)B cells protect againstPlasmodium yoelii infection and express Granzyme B

PLOS ONE

Authors: Parra, Marcela; Weitner, Megan; Yang, Amy; Akue, Adovi; Liu, Xia; Schmidt, Thomas; Allman, Windy R.; Akkoyunlu, Mustafa; Derrick, Steven C.

Abstract

To better understand anti-malaria protective immune responses, we examined the cellular mechanisms that govern protective immunity in a murinePlasmodium yoelii17X NL (PyNL) re-infection model. Initially, we confirmed that immune B cells generated during a primary PyNL infection were largely responsible for protection from a second PyNL infection. Using the previously identified memory B cell markers CD80, PD-L2, and CD73, we found an increase in the frequency of CD80(-)PD-L2(-)CD73(+)B cells up to 55 days after a primary PyNL infection and at 4-6 days following a second PyNL infection. Moreover, injection of enriched immune CD19(+)CD73(+)B cells into nonimmune mice were significantly more protective against a PyNL infection than CD73(-)B cells. Interestingly, a substantial fraction of these CD73(+)B cells also expressed IgM and granzyme B, a biomolecule that has been increasingly associated with protective responses against malaria.

Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies

ANNALS OF HEMATOLOGY

Authors: Viardot, Andreas; Locatelli, Franco; Stieglmaier, Julia; Zaman, Faraz; Jabbour, Elias

Abstract

The B cell surface antigen CD19 is a target for treating B cell malignancies, such as B cell precursor acute lymphoblastic leukemia and B cell non-Hodgkin lymphoma. The BiTE (R) immuno-oncology platform includes blinatumomab, which is approved for relapsed/refractory B cell precursor acute lymphoblastic leukemia and B cell precursor acute lymphoblastic leukemia with minimal residual disease. Blinatumomab is also being evaluated in combination with other agents (tyrosine kinase inhibitors, checkpoint inhibitors, and chemotherapy) in various treatment settings, including frontline protocols. An extended half-life BiTE molecule is also under investigation. Patients receiving blinatumomab may experience cytokine release syndrome and neurotoxicity; however, these events may be less frequent and severe than in patients receiving other CD19-targeted immunotherapies, such as chimeric antigen receptor T cell therapy. We review BiTE technology for treating malignancies that express CD19, analyzing the benefits and limitations of this bispecific T cell engager platform from clinical experience with blinatumomab.